Revised SPC: Blincyto (blinatumomab) 38.5 micrograms powder for concentrate and solution for infusion

Indication has been updated to clarify that patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

Source:

electronic Medicines compendium